Bolt Biotherapeutics, Inc.
BOLT
$0.37
$0.0154.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 1.14M | 1.28M | 5.27M | 2.09M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 1.14M | 1.28M | 5.27M | 2.09M |
| Cost of Revenue | 11.72M | 13.79M | 15.43M | 16.53M | 16.32M |
| Gross Profit | -11.72M | -12.64M | -14.16M | -11.26M | -14.23M |
| SG&A Expenses | 3.95M | 3.80M | 4.87M | 5.84M | 5.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.67M | 17.58M | 20.31M | 22.37M | 21.86M |
| Operating Income | -15.67M | -16.44M | -19.03M | -17.09M | -19.77M |
| Income Before Tax | -15.94M | -15.18M | -21.20M | -10.81M | -17.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.94M | -15.18M | -21.20M | -10.81M | -17.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.94M | -15.18M | -21.20M | -10.81M | -17.90M |
| EBIT | -15.67M | -16.44M | -19.03M | -17.09M | -19.77M |
| EBITDA | -15.24M | -16.00M | -18.58M | -16.63M | -19.30M |
| EPS Basic | -0.83 | -0.40 | -0.56 | -0.28 | -0.47 |
| Normalized Basic EPS | -0.48 | -0.25 | -0.29 | -0.25 | -0.29 |
| EPS Diluted | -0.83 | -0.40 | -0.56 | -0.28 | -0.47 |
| Normalized Diluted EPS | -0.48 | -0.25 | -0.29 | -0.25 | -0.29 |
| Average Basic Shares Outstanding | 38.29M | 38.25M | 38.13M | 38.07M | 37.94M |
| Average Diluted Shares Outstanding | 38.29M | 38.25M | 38.13M | 38.07M | 37.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |